Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France

Michael Mounie (), Nadège Costa, Cécile Conte, Dominique Petiot, Didier Fabre, Fabien Despas (), Maryse Lapeyre-Mestre (), Guy Laurent (), Nicolas Savy () and Laurent Molinier ()
Additional contact information
Michael Mounie: UEME - Unité d'Evaluation Médico-Economique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse, LEASP - Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale
Nadège Costa: LEASP - Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale, UEME - Unité d'Evaluation Médico-Economique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
Cécile Conte: UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse
Dominique Petiot: Département d'Information Médicale [CHU Toulouse] - Pôle Santé publique et médecine publique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
Didier Fabre: Département d'Information Médicale [CHU Toulouse] - Pôle Santé publique et médecine publique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
Fabien Despas: UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse, CIC 1436 - Centre d'investigation clinique de Toulouse - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale - Pôle Santé publique et médecine publique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
Maryse Lapeyre-Mestre: UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse, CIC 1436 - Centre d'investigation clinique de Toulouse - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale - Pôle Santé publique et médecine publique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
Guy Laurent: IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale
Nicolas Savy: IMT - Institut de Mathématiques de Toulouse UMR5219 - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - INSA Toulouse - Institut National des Sciences Appliquées - Toulouse - INSA - Institut National des Sciences Appliquées - UT - Université de Toulouse - UT2J - Université Toulouse - Jean Jaurès - UT - Université de Toulouse - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - CNRS - Centre National de la Recherche Scientifique
Laurent Molinier: UEME - Unité d'Evaluation Médico-Economique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse, LEASP - Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps - UT3 - Université Toulouse III - Paul Sabatier - UT - Université de Toulouse - INSERM - Institut National de la Santé et de la Recherche Médicale, Département d'Information Médicale [CHU Toulouse] - Pôle Santé publique et médecine publique [CHU Toulouse] - CHU Toulouse - Centre Hospitalier Universitaire de Toulouse

Post-Print from HAL

Abstract: Background: Lymphomas are costly diseases that suffer from a lack of detailed economic information, notably in a real-world setting. Decision-makers are increasing the search for Real-World Evidence (RWE) to assess the impact, in real-life, of healthcare management and to support their public decisions. Thus, we aimed to assess the real-world net costs of the active treatment phases of adult Hodgkin Lymphoma (HL), Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). Methods: We performed a retrospective cohort study using population-based data from a national representative sample of the French population covered by the health insurance system. Cost analysis was performed from the French health insurance perspective and took into account direct and sick leave compensation costs (e2,018). Healthcare costs were studied over the active treatment phase. We used multivariate modeling to adjust cost differences between lymphoma subtypes. Results: Analyses were performed on 224 lymphoma patients and 896 controls. The mean additional monthly costs due to HL, FL and DLBCL patients were respectively e5,188, e3,242 and e7,659 for the active treatment phase. The main additional cost driver was principally inpatient stay (hospitalization costs and costly cancer-related drugs), followed by outpatient medication and productivity loss. When adjusted, DLBCL remains significantly the most costly lymphoma subtype. Conclusion: This study provides an accurate assessment of the main lymphoma subtypes related cost with high magnitude of details in a real-world setting. We underline where potential cost saving could be realized via the use of biosimilar medication, and where lymphoma management could be improved with the early management of adverse events.

Keywords: French health insurance; real-world evidence; administrative claims databases; cost evaluation; Lymphoma (search for similar items in EconPapers)
Date: 2020
New Economics Papers: this item is included in nep-ias
Note: View the original document on HAL open archive server: https://hal.science/hal-02533775v1
References: Add references at CitEc
Citations:

Published in Journal of Medical Economics, 2020, 23 (3), pp.235-242. ⟨10.1080/13696998.2019.1702990⟩

Downloads: (external link)
https://hal.science/hal-02533775v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02533775

DOI: 10.1080/13696998.2019.1702990

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().